文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA配体PET用于早期去势抵抗性前列腺癌:一项回顾性单中心研究

PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study.
PubMed 文献 · J Nucl Med · 2020-05-22

本研究回顾性分析55例早期去势抵抗性前列腺癌(CRPC,前列腺特异性抗原≤3 ng/mL)患者,由3名设盲读者独立判读PSMA PET/CT及其CT成分。PSMA PET/CT在41/55(75%)患者中阳性,25/55(45%)为M1期病变,观察者间一致性Fleiss κ=0.77。作者认为PSMA PET/CT对早期CRPC有价值,应纳入欧洲泌尿外科学会与前列腺癌工作组3的CRPC入组标准。

要点

  • 早期CRPC(PSA≤3 ng/mL)患者中PSMA PET/CT阳性率为75%(41/55)。
  • 45%(25/55)患者检出M1期病变,29%(16/55)仅为局部病变。
  • 观察者间一致性为Fleiss κ=0.77,按Landis和Koch标准为实质性一致。

核心结论

  • PSMA PET/CT在75%的早期CRPC患者中定位前列腺癌病灶,在45%中检出M1期病变。
  • 作者认为早期CRPC的检出有助于对局部或寡转移病变采用延缓疾病的治疗。
  • 作者认为PSMA PET/CT对早期CRPC有价值,应纳入欧洲泌尿外科学会与前列腺癌工作组3的CRPC入组标准。

研究设计与样本

  • 回顾性单中心研究,从本机构数据库识别55例早期CRPC(前列腺特异性抗原≤3 ng/mL)患者。
  • PSMA PET/CT及其CT成分由3名设盲读者独立判读。
  • 主要终点为按患者的检出率,次要终点为观察者间一致性与PET阳性的预测因素。

主要发现

  • PSMA PET/CT在41/55(75%)患者中为阳性。
  • 16/55(29%)患者仅为局部病变,25/55(45%)患者为M1期病变。
  • 总体PSMA PET/CT观察者间一致性按Landis和Koch标准为实质性一致(Fleiss κ=0.77)。

关键数值与推荐

  • 早期CRPC定义为前列腺特异性抗原≤3 ng/mL。
  • 观察者间一致性按Landis和Koch标准判定,Fleiss κ=0.77为实质性一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The low detection rate of conventional imaging and unspecific fluctuations in prostate-specific antigen can hamper early diagnosis of castration-resistant prostate cancer (CRPC). We thus assessed the value of prostate-specific membrane antigen (PSMA) PET/CT in the detection of early CRPC (prostate-specific antigen ≤ 3 ng/mL). Methods: We identified 55 patients with early CRPC from our institutional database. PSMA PET/CT and its CT component were interpreted independently by 3 masked readers. The primary endpoint was the per-patient detection rate; secondary endpoints were interobserver agreement and predictors of PET positivity. Results: PSMA PET/CT was positive in 41 of 55 (75%) patients. Sixteen of 55 (29%) patients had local disease only, and 25 of 55 (45%) had M1 disease. Overall, PSMA PET/CT interobserver agreement was substantial by Landis and Koch criteria (Fleiss κ = 0.77). Conclusion: PSMA PET/CT localized prostate cancer lesions in 75% of patients and M1 disease in 45%. Detection of early CRPC facilitates disease-delaying therapies for local or oligometastatic disease. PSMA PET/CT is of value in early CRPC and should be included in the CRPC entry criteria of the European Association of Urology and Prostate Cancer Working Group 3.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Weber M, Kurek C, Barbato F, et al. PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. J Nucl Med. 2020. PMID: 32444377. doi:10.2967/jnumed.120.245456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。